Sentiment-Signal
23,7
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Unternehmen & Branche
| Name | Evolus, Inc. |
|---|---|
| Ticker | EOLS |
| CIK | 0001570562 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 335,1 Mio. USD |
| Beta | 1,00 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 297,176,000 | -51,641,000 | -0.80 | 225,868,000 | -23,106,000 |
| 2025-09-30 | 10-Q | 68,967,000 | -15,737,000 | -0.24 | 218,997,000 | -28,760,000 |
| 2025-06-30 | 10-Q | 69,387,000 | -17,142,000 | -0.27 | 228,803,000 | -18,652,000 |
| 2025-03-31 | 10-Q | 68,522,000 | -18,892,000 | -0.30 | 213,361,000 | -6,604,000 |
| 2024-12-31 | 10-K | 266,274,000 | -50,420,000 | -0.81 | 232,569,000 | 5,522,000 |
| 2024-09-30 | 10-Q | 61,085,000 | -19,170,000 | -0.30 | 229,608,000 | 5,890,000 |
| 2024-06-30 | 10-Q | 66,909,000 | -11,350,000 | -0.18 | 233,772,000 | 19,314,000 |
| 2024-03-31 | 10-Q | 59,333,000 | -13,109,000 | -0.22 | 226,176,000 | 18,443,000 |
| 2023-12-31 | 10-K | 202,085,000 | -61,685,000 | -1.08 | 188,998,000 | -20,689,000 |
| 2023-09-30 | 10-Q | 50,019,000 | -16,923,000 | -0.30 | 167,971,000 | -19,368,000 |
| 2023-06-30 | 10-Q | 49,346,000 | -18,140,000 | -0.32 | 168,983,000 | -6,963,000 |
| 2023-03-31 | 10-Q | 41,721,000 | -14,791,000 | -0.26 | 160,235,000 | 6,949,000 |
| 2022-12-31 | 10-K | 148,616,000 | -74,412,000 | -1.33 | 177,983,000 | 18,499,000 |
| 2022-09-30 | 10-Q | 33,899,000 | -20,276,000 | -0.36 | 192,719,000 | 29,220,000 |
| 2022-06-30 | 10-Q | 37,163,000 | -23,471,000 | -0.42 | 210,919,000 | 46,861,000 |
| 2022-03-31 | 10-Q | 33,908,000 | -17,501,000 | -0.31 | 220,662,000 | 67,248,000 |
| 2021-12-31 | 10-K | 99,673,000 | -46,810,000 | -0.94 | 257,483,000 | 81,876,000 |
| 2021-09-30 | 10-Q | 26,677,000 | -19,433,000 | -0.35 | 215,220,000 | 97,404,000 |
| 2021-06-30 | 10-Q | 26,098,000 | -15,601,000 | -0.31 | 239,863,000 | 106,138,000 |
| 2021-03-31 | 10-Q | 12,241,000 | 6,401,000 | 0.16 | 157,198,000 | 23,289,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Avelar Rui | Officer, See Remarks | Open Market Sale | -3,119 | 4.75 | -14,815.25 | -8,4% | |
| 2026-03-20 | MOATAZEDI DAVID | Director, Officer, See Remarks | Open Market Sale | -13,669 | 4.75 | -64,929.12 | -36,8% | |
| 2026-03-17 | Avelar Rui | Officer, See Remarks | Open Market Sale | -29,996 | 4.89 | -146,629.45 | -83,2% | |
| 2025-12-22 | Avelar Rui | Officer, See Remarks | Open Market Sale | -2,261 | 7.15 | -16,167.73 | -9,2% | |
| 2025-12-22 | MOATAZEDI DAVID | Director, Officer, See Remarks | Open Market Sale | -10,539 | 7.15 | -75,361.23 | -42,7% | |
| 2025-08-22 | Yamagishi-Dressler Tomoko | Officer, Chief Marketing Officer | Open Market Sale | -5,722 | 7.51 | -42,972.22 | -24,4% | |
| 2025-08-15 | Stewart Brady | Director | Open Market Purchase | 30,000 | 6.82 | 204,486.00 | +116,0% | |
| 2025-06-16 | MOATAZEDI DAVID | Director, Officer, See Remarks | Open Market Sale | -16,582 | 9.89 | -164,054.02 | -93,1% | |
| 2025-06-13 | MOATAZEDI DAVID | Director, Officer, See Remarks | Open Market Sale | -111,323 | 10.05 | -1,119,141.25 | -634,8% | |
| 2025-06-09 | White Albert G III | Director | Open Market Purchase | 20,000 | 9.45 | 189,000.00 | +107,2% | |
| 2025-05-13 | Beaver Sandra | Officer, Chief Financial Officer | Open Market Sale | -6,494 | 10.02 | -65,069.88 | -36,9% | |
| 2025-05-12 | Avelar Rui | Officer, See Remarks | Open Market Sale | -3,385 | 9.87 | -33,396.75 | -18,9% | |
| 2025-05-12 | MOATAZEDI DAVID | Director, Officer, See Remarks | Open Market Sale | -15,787 | 9.87 | -155,756.12 | -88,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.